Drug
Ibutilide
Ibutilide is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
83.3%
Based on 5 completed trials
Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
100%(5 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_4
3
50%
Ph not_applicable
2
33%
Ph phase_2
1
17%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 4Post-market surveillance
3(50.0%)
N/ANon-phased studies
2(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (16.7%)
Phase 43 (50.0%)
N/A2 (33.3%)
Trials by Status
completed583%
terminated117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_4
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT04675788
completedphase_4
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT03834883
terminatednot_applicable
ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization
NCT03370536
completedphase_4
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT02513940
completednot_applicable
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
NCT01014741
Clinical Trials (6)
Showing 6 of 6 trials
NCT04675788Phase 4
Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT03834883Phase 4
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT03370536Not Applicable
ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization
NCT02513940Phase 4
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT01014741Not Applicable
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
NCT01929083Phase 2
Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6